Novo Nordisk's AI Drive Meets a Harsh Pricing Reality

Novo Nordisk shares fall 50% from highs on 2026 profit warning, US market loss to Eli Lilly, and generic price cuts. The firm bets on AI model GPT-Rosalind to accelerate R&D.

Novo Nordisk shares, trading at €34.44, find themselves caught in a powerful crosscurrent. The stock is down nearly 23% year-to-date and sits roughly 50% below its 52-week high of €70.13 from June 2025. This steep decline reflects a stark financial warning for 2026, with the company forecasting a revenue and adjusted profit drop of between 5% and 13% on a constant currency basis.

The pressure is coming from multiple directions. In the crucial US obesity treatment market, competitor Eli Lilly has seized the initiative, now commanding approximately 60% market share with its drug tirzepatid. Clinical data consistently shows higher average weight reduction for Lilly's product compared to Novo's Wegovy, creating a structural disadvantage that pricing moves alone cannot fix.

Simultaneously, the looming threat of generic competition is forcing dramatic price cuts. In India, the arrival of cheaper semaglutid copies has led Novo Nordisk to slash prices for Wegovy and Ozempic by up to 48%. This aggressive discounting, alongside US pricing pressure and upcoming patent expirations for key products, is squeezing margins hard.

Amid this financial strain, the Danish pharmaceutical giant is making a bold technological bet. On April 17-18, 2026, Novo Nordisk unveiled "GPT-Rosalind," a specialized AI model for biology and translational medicine developed in collaboration with OpenAI. The ambition is to drastically shorten the traditional 10 to 15-year drug development timeline. Internally, the model has reportedly outperformed 95% of human experts in predicting RNA sequences, with pilot programs active across the entire value chain. Full integration is targeted for the end of 2026.

On the clinical front, there are pockets of progress. Data for the oral formulation of Wegovy showed an average weight loss of 14% over 64 weeks, compared to 2.4% for placebo. About 28% of participants on the 25mg maintenance dose lost more than one-fifth of their body weight. Furthermore, an April 2026 study in Nature used AI to analyze over 400,000 social media reports on GLP-1 drugs, confirming gastrointestinal issues as the most common side effect at 37% but also uncovering less documented symptoms like menstrual cycle changes in nearly 4% of female users.

To support its share price, Novo Nordisk is actively deploying capital. A share buyback program totaling DKK 15 billion, initiated in February, is underway. Since mid-April, over 11 million B-shares have been repurchased, with the current tranche running until early May 2026. With a forward P/E ratio of around 11, the stock is considered cheap by historical measures.

All eyes are now on the company's first-quarter report due on May 6. Investors will scrutinize early sales figures for the Wegovy pill and seek updates on the development timeline for the combination therapy CagriSema. The report will provide critical evidence on whether the company's AI-driven future can gain traction fast enough to offset the intense pricing pressures defining its present.